NCT07516093Phase 3Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Study sponsor: Nurix Therapeutics, Inc. · NRIX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2029-10Estimated
Enrollment · participants620Estimated
Source updated2026-08-31Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)

+ After

Measure: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) Measure: Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRC

Recruitment status changed

− Before

Not yet recruiting

+ After

Recruiting

Check registry source